Treatment for cancer patients must prioritize preventing and controlling nausea and vomiting (N&V). One of the most prevalent and upsetting acute adverse effects of chemotherapy-induced nausea and vomiting (N&V) is cancer treatment. It can significantly lower a patient's quality of life and happens in up to 80% of patients. The perceptual feeling of nausea is an unpleasant, wave-like sensation in the epigastrium and/or back of the throat that may lead to vomiting (emesis). Emesis, the violent evacuation of stomach, duodenal, or jejunal contents through the oral canal, is referred to as vomiting. Retching, also known as dry heaves, involves the stomach and esophageal motions of vomiting without the evacuation of vomitus. Understanding the neurophysiological systems that regulate nausea and vomiting (N&V) has advanced. The central nervous system regulates or mediates both, but through different ways. The autonomic nervous system is the mechanism that causes nausea.
A complicated response that includes the convergence of afferent input is stimulated during vomiting. Neurotransmitters in the chemoreceptor trigger zone, the vomiting center (said to be situated in the nucleus tractus solitarius), and enterochromaffin cells in the gastrointestinal tract emit efferent impulses. These neurotransmitters include serotonin, substance P, and dopamine. These signals are sent to the respiratory center, salivation center, and abdominal muscles. The relative importance of these several routes, which result in N&V symptoms, is complicated. It is proposed to explain agents' varying emetogenicity (intrinsic emetogenicity and mitigating variables [i.e., dose, administration method, and exposure length]) and emetogenic profile (i.e., time to onset, intensity, and duration of symptoms).
Market Dynamics
Chemotherapy-induced nausea and vomiting (CINV) drugs are given to patients who undergo chemotherapy treatment to prevent nausea and vomiting. An increase in the number of patients undergoing chemotherapy is expected to drive the market growth over the forecast period. For instance, according to the data provided by the Centers for Disease Control and Prevention, in November 2022, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. each year.
Key features of the study:
- This report provides an in-depth analysis of the global cancer chemotherapy associated nausea and vomiting therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cancer chemotherapy associated nausea and vomiting therapeutics market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy’s Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cancer chemotherapy associated nausea and vomiting therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer chemotherapy associated nausea and vomiting therapeutics market
Detailed Segmentation:
- Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, Type:
- Acute CINV
- Delayed CINV
- Anticipatory nausea and emesis
- Breakthrough CINV/Refractory CINV
- Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, Drug Class:
- Dopamine Receptor Antagonists
- Metoclopramide
- Chlorpromazine
- Prochlorperazine
- Haloperidol
- Droperidol
- Others
- Serotonin (5-HT3) receptor Antagonists
- Ondansetron
- Granisetron
- Palonosetron
- Dolasetron
- Others
- Substance P/NK-1 Antagonists
- Aprepitant
- Fosaprepitant
- Netupitant
- Others
- Corticosteroids
- Dexamethasone
- Methylprednisolone
- Others
- Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration:
- Oral
- Parenteral
- Transdermal Patch
- Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eisai Co., Ltd.
- Pharmanovia
- Novartis AG
- Merck & Co., Inc.
- Helsinn Healthcare SA
- Reddy’s Laboratories Ltd.
- Validus Pharmaceuticals LLC
- LGM Pharma
- Astellas Pharma Inc.
- AdvaCare Pharma
- Norgine
- PV Pharma
- Fresenius Kabi
- Lupin
- Hetero Healthcare Limited.
- Sino Biopharmaceutical Limited
- Glenmark Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd
- OPKO Health, Inc.
- Weefsel Pharma
- Pfizer Inc.
- Rosemont Pharmaceuticals Ltd.
- Starton Therapeutics.
